Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Conatus Pharmaceuticals CNAT

Healthcare Biotechnology
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes... see more

Recent & Breaking News (NDAQ:CNAT)

EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

GlobeNewswire October 18, 2017

Technical Insights on Biotech Stocks -- Conatus Pharma, Immunomedics, INSYS Therapeutics, and InVivo Therapeutics

PR Newswire October 17, 2017

12 Biggest Mid-Day Gainers For Friday

Benzinga.com  October 6, 2017

Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer

GlobeNewswire August 31, 2017

Conatus to Present at Rodman & Renshaw Global Investment Conference

GlobeNewswire August 29, 2017

Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis

GlobeNewswire August 14, 2017

Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates

GlobeNewswire August 2, 2017

Investor Network: Conatus Pharmaceuticals Inc. to Host Earnings Call

Accesswire August 2, 2017

Conatus Pharmaceuticals to Report Second Quarter 2017 Financial Results

GlobeNewswire July 26, 2017

Conatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of $7 Million Payment

GlobeNewswire July 6, 2017

FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

GlobeNewswire June 26, 2017

Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference

GlobeNewswire June 16, 2017

Research Reports Coverage on Biotech Stocks -- Achaogen, Bellicum Pharma, Coherus BioSciences, and Conatus Pharma

PR Newswire June 1, 2017

Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire May 16, 2017

Mid-Morning Market Update: Markets Open Lower; Macy's Profit Misses Expectations

Benzinga.com  May 11, 2017

Conatus Announces Pricing of Public Offering of Common Stock

GlobeNewswire May 11, 2017

Conatus Announces Proposed Public Offering of Common Stock

GlobeNewswire May 10, 2017

Conatus Pharmaceuticals Reports First Quarter 2017 Financial Results and Program Updates

GlobeNewswire May 4, 2017

Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH Cirrhosis

GlobeNewswire May 4, 2017

Conatus Pharmaceuticals to Report First Quarter 2017 Financial Results

GlobeNewswire April 27, 2017